Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating The ...
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...
Jasper Therapeutics, Inc. announced promising results from its BEACON Phase 1b/2a study of briquilimab, an antibody therapy targeting mast cell diseases like chronic spontaneous urticaria (CSU). In ...
HENDERSON, Ky. (WEHT) – The question has often been asked: If the Mid-States Corridor is built to replace U.S. Highway 231, what happens to the existing highway? It could be placed into the hands of ...
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting ...
Jasper Therapeutics, Inc. (($JSPR)) announced an update on their ongoing clinical study. Jasper Therapeutics, Inc. is conducting a clinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback